Evidence map›Paper›PMID 41039732›Full record

Trial reportEuropean journal of heart failure2025

Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS-HF.

João Pedro Ferreira, Muthiah Vaduganathan, Brian L Claggett, Ian Kulac, John W Ostrominski, Akshay S Desai, Pardeep S Jhund, Carolyn S P Lam, Michele Senni, Sanjiv J Shah and 8 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

João Pedro FerreiraUnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.ORCID https://orcid.org/0000-0002-2304-6138
Muthiah VaduganathanBrigham and Women's Hospital, Boston, MA, USA.
Brian L ClaggettBrigham and Women's Hospital, Boston, MA, USA.
Ian KulacBrigham and Women's Hospital, Boston, MA, USA.
John W OstrominskiBrigham and Women's Hospital, Boston, MA, USA.
Akshay S DesaiBrigham and Women's Hospital, Boston, MA, USA.
Pardeep S JhundBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Carolyn S P LamNational Heart Centre Singapore, Singapore, Singapore.
Michele SenniUniversity of Milano-Bicocca, Milan, Italy.
Sanjiv J ShahNorthwestern Memorial Hospital, Chicago, IL, USA.
Adriaan A VoorsUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Bertram PittDepartment of Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Katja RohwedderBayer AG, Global Medical Affairs, Berlin, Germany.
Meike BrinkerBayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany.
Patrick SchloemerBayer AG, Research & Development, Pharmaceuticals, Berlin, Germany.
John J V McMurrayBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Scott D SolomonBrigham and Women's Hospital, Boston, MA, USA.
Faiez ZannadUniversité de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsFinerenone improved heart failure (HF) outcomes in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Clinical decision-making around initiation of mineralocorticoid receptor antagonists often relies on measures of kidney function and serum potassium (K METHODS AND

resultsFour mutually exclusive categories were created: (1) K

conclusionsNo significant heterogeneity was found on the effect of finerenone to reduce primary outcome events. Still, adverse events and treatment discontinuation were more frequent among patients with low eGFR and/or high K

Indexed as

Glomerular Filtration RateHeart FailureKidneyNaphthyridinesPotassiumStroke VolumeAgedFemaleHumansMaleMiddle AgedMineralocorticoid Receptor AntagonistsTreatment OutcomefinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesPotassiumFinerenoneHeart failure with mildly reduced ejection fractionHeart failure with preserved ejection fractionSerum potassiumEstimated glomerular filtration rate

Identifiers

PMID41039732
PMCPMC12765369

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.